Search alternatives:
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
ms decrease » _ decrease (Expand Search), mean decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ms » 500 ms (Expand Search), 50 mg (Expand Search), 50 mm (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
ms decrease » _ decrease (Expand Search), mean decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ms » 500 ms (Expand Search), 50 mg (Expand Search), 50 mm (Expand Search)
-
7321
-
7322
-
7323
Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi...
Published 2025“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
-
7324
Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi...
Published 2025“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
-
7325
Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi...
Published 2025“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
-
7326
Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi...
Published 2025“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
-
7327
Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi...
Published 2025“…Treatment with Nu0.5 resulted in a numerically decreased EASI score (-11.9%, [-34.9%, 11.1%], p > 0.05), which is comparable with placebo group (-2.9%, [-21.5%, 15.6%], p > 0.05). …”
-
7328
-
7329
-
7330
Gonadal development and sex ratios as a function of TL.
Published 2013“…</p> <p>(b) Sex ratios (female:male) as a function of TL. Data were sorted into 50 mm TL intervals. …”
-
7331
-
7332
Context and impact of elevated antisense expression levels in the Δ<i>rho</i> mutant.
Published 2016“…Each annotated gene is represented by a point. There is a strong negative correlation between sense and antisense expression in the Δ<i>rho</i> mutant (Pearson correlation coefficient r = -0.73) that is also visible but much weaker in the wild-type (r = -0.30). …”
-
7333
A) Perfusate oxygenation (ΔPO) during reperfusion
Published 2011“…After 50 minutes, ΔPOdecreased in untreated lungs compared to baseline. …”
-
7334
-
7335
Heatmaps with different genetic linkage and migration rate.
Published 2021“…<p>Heatmaps showing the average <i>Rescue</i> frequency for 100 <b>(A-C)</b> and 300 generations <b>(D-F)</b>. Linkage ranging from 0–50 cM, migration rate from 0.1–20% per generation. …”
-
7336
-
7337
Effects of Y-P30 on expression and phosphorylation of glutamate receptors, Src, and ERK.
Published 2019“…(A) Representative blot at DIV 20; per lane, 50% of a lysate from a vehicle-treated control and a 60 min Y-P30-treated OTC was loaded on the left and the right side of a gel. …”
-
7338
-
7339
-
7340
Participant characteristics.
Published 2025“…The risk factor prevalences that decreased significantly were: inadequate physical activity from 5.0% in 2014 to 3.6% in 2023 (p=0.003), and current smoke tobacco use from 9.6% in 2014, to 8.3% in 2023 (p= 0.046). …”